Pharmaceutical, biotech, and medical device sales teams work in a compliance-shaped environment with named-prescriber targets, therapeutic area fit, formulary posture, and strict engagement rules. The lead is sometimes an individual healthcare professional and sometimes an integrated delivery network or payer. The signals that predict a formulary win or a bound device contract read therapeutic area match, prescribing or ordering volume where ethically available, formulary tier status, access-and-reimbursement posture, and HCP engagement cadence under PhRMA Code or AdvaMed Code. Strkr runs lead scoring across those signals under a HIPAA posture with a Business Associate Agreement available and cites every driver on the record.
Generic B2B scorers were trained on private-sector software buyers. Apply them to a pharmaceutical target universe and the model confidently promotes a resident with a sample request above a high-volume specialist on an active formulary review. The signals that actually predict a formulary win or a bound device contract live in therapeutic area match, prescribing or ordering volume, formulary posture, and the compliance posture of the engagement cadence.
Therapeutic area match is a hard filter, not a soft signal. A product calibrated for cardiology against a dermatology-focused prescriber is noise. Generic scorers see HCP and move on. Strkr maps NPI taxonomy to a therapeutic area hierarchy and prioritizes the in-area prescribers while flagging out-of-area for exclusion.
Open prescribing or claims data (where ethically available and permitted) is the strongest predictor of fit for pharma and device sales. Generic scorers never see it. Strkr integrates with licensed data providers to enrich records with prescribing volume for the therapeutic class, with every pull logged for compliance.
An integrated delivery network with the product on preferred tier buys differently than one with the product in restricted use. Generic scorers do not read formulary status. Strkr tags formulary tier, prior authorization posture, and step-edit requirements on the IDN or payer record.
Access and reimbursement posture (payer mix, coverage posture, access barriers, specialty pharmacy requirements) shapes the opportunity. Generic scorers compress it to zero. Strkr tags the payer mix on the account and weights access-and-reimbursement signals against product fit.
HCP engagement runs under PhRMA Code or AdvaMed Code. Over-aggressive cadence raises compliance flags rather than scoring a lead. Generic scorers reward volume. Strkr reads cadence sensitivity, respects suppression windows, and scores engagement against a compliant baseline.
Investigators active on a trial program buy differently than non-investigators. The engagement path, the budget authority, and the compliance posture differ. Generic scorers do not read trial posture. Strkr tags clinical trial involvement on the HCP record and weights accordingly.
The Strkr scoring model for pharmaceutical, biotech, and medical device accounts reads a set of signals rather than compressing everything into one generic engagement number. Each signal is cited on the record so the account executive sees why the lead is scored where it is and so the sales operations lead can tune the weighting to the actual deal shape. The fields are the ones the pharma or device commercial team already works with and the model surfaces them in one view.
The target signal reads the entity type (named HCP, integrated delivery network, payer, group purchasing organization) and weights against product fit. The ideal customer profile is defined against the target type the product fits.
The therapeutic area signal maps the NPI taxonomy code to a therapeutic area hierarchy and prioritizes in-area targets while flagging out-of-area for exclusion. Multi-specialty providers get tagged on all applicable areas.
The volume signal reads prescribing or ordering volume for the therapeutic class from licensed data (where ethically available and permitted) and tags the record with the tier band. The sales operations lead configures the band weighting.
The formulary signal reads formulary tier, prior authorization posture, and step-edit requirements on the IDN or payer record. The score reflects whether the account is open, friction-constrained, or closed to the product.
The access signal reads payer mix, coverage posture, and access barriers (specialty pharmacy requirements, hub services involvement) and weights the opportunity accordingly. The score reflects the real-world buy-ability of the account.
The trial signal reads active investigator roles, trial history, and ongoing clinical program involvement. Investigators engaged on a program buy differently than non-investigators. The score reflects the trial relationship on the record page.
The stakeholder signal reads which titles on the account are engaging and treats a formulary committee chair email differently from a resident newsletter sign-up. The score cites the engaging contacts and their roles.
The historical signal reads the shape of your closed formulary wins or bound device contracts at the same stage: therapeutic area mix, volume distribution, formulary posture mix. The model weights signals that correlate with your actual wins rather than a generic benchmark.
A score that lands on the record as a bare number gets ignored because nobody trusts a number without a reason. The record page shows the numeric score, the top five drivers that produced it, the cited fields each driver came from, and a counterfactual that shows what would move the score up. The explainability panel is the thing that drives adoption inside a compliance-sensitive pharma or device commercial organization.
The score is a zero-to-one-hundred number scoped to the pharma or device segment, not an unscoped global ranking. A target scored eighty-five sits in the top band for its segment, not against unrelated verticals. Field teams can compare like-for-like without the segment collapse.
The record shows the top five drivers behind the current score with the cited records. The field rep sees the signals that drove the ranking without clicking into a separate tool. The common failure of a scoring tool returning a number the sales team ignores because the number has no explanation gets closed off.
Every driver cites the field it read: the NPI taxonomy mapping, the volume tier, the formulary status, the engaging stakeholder record. The field rep clicks through to the field, verifies the data, and files a correction if the source is wrong. The feedback loop improves the model.
The counterfactual panel shows what would move the score up. Example: confirmation of P&T committee review would move the lead from sixty-eight to seventy-nine, or engagement from the formulary chair would move it to eighty-six. The field rep works with context rather than a bare number.
The record page shows the score trajectory over the last ninety days with the events that moved it. A target that climbed from forty to seventy over a quarter looks different from a target that has been flat at sixty for a year. The field rep reads the trend without a reporting ticket.
Every score shows the model version and the last calibration date. Tenants on an older calibration can see it. The sales operations lead schedules recalibrations as the market shifts without wondering whether the score reflects the latest signals.
A lead score that sits in a dashboard the field team never opens is a dashboard metric, not a workflow. The Strkr scoring model lands the score on the HCP record, the IDN record, the payer record, and the daily working list the medical science liaison or sales representative opens in the morning. The score drives routing, prioritization, and the first-touch opener draft that Strkr AI writes with the drivers cited and the compliance posture respected.
The daily target list ranks accounts by score within the segment the field rep owns. Filters narrow the list to high-volume prescribers, IDNs in a formulary review window, or investigators on an active trial. The rep opens one list, not six dashboards, and works top-down.
Routing rules read the score and the volume tier. High-volume prescribers route to senior field reps, mid-tier to standard pods, lower-tier to the specialist pod. The rules read the target type too so a payer goes to the payer account manager rather than an HCP rep.
Strkr AI drafts the first-touch opener against the top drivers. The opener references the therapeutic area, the formulary posture, and the engaging stakeholder without the field rep hunting for the context. The rep reviews, edits, and sends. The opener is a draft, not a sent email.
The cadence engine respects compliance guardrails for HCP engagement under PhRMA Code or AdvaMed Code. Over-aggressive outreach does not boost the score; it suppresses the engagement signal and routes the account to a human review. The common failure of burning a target on cadence gets avoided.
The trigger alert fires when an account enters a buying window: a formulary review scheduled, a trial launch, a new indication approval, a KOL engagement. The field rep sees the alert in the daily queue with the context attached.
The field manager sees the score distribution across the team and the compliance posture: how many targets are in the active window, how many have an engaged formulary chair, and how the mix compares to the segment benchmark. Coaching runs on a shared view of the pipeline shape.
Pharma and device commercial teams work under PhRMA Code, AdvaMed Code, HIPAA, and additional state-level marketing laws. Strkr runs under a HIPAA posture with a Business Associate Agreement available, keeps a SOC 2 Type II audit in progress, and keeps the data portable. The compliance review runs against documentation rather than a sales pitch.
Strkr is HIPAA compliant with a Business Associate Agreement available. The scoring model reads vendor-side account and contact records; protected health information is not a model signal. The posture lines up with what the compliance office expects to see.
The Strkr SOC 2 Type II audit is in progress through 2026-Q4 with the controls catalog available on request. Vendor security review teams see the posture, the controls in scope, and the audit timeline so the review is a conversation rather than a question.
Every claims or prescribing data pull from a licensed provider is logged with the user, the timestamp, the record scope, and the business justification. The compliance team runs its review against the log rather than against tribal memory.
The score, the drivers, and the signal history are available through the open API so the data team can pull them into the warehouse. Scores are not trapped behind a product-specific UI. The compliance team can audit the record flow on its own schedule.
Every account record, score history row, and driver citation is exportable in a structured format on demand. The organization is never locked into a format it cannot read elsewhere. Vendor change becomes a workflow, not a reconstruction project.
Access controls scope visibility by territory and therapeutic area. A cardiovascular rep does not read the oncology queue. The common failure of a scoring tool with wide-open permissions gets closed off.
Strkr lead scoring for the pharmaceutical industry reads therapeutic area, volume tier, formulary posture, access and reimbursement, trial posture, and stakeholder engagement. HIPAA compliant with a BAA available. Fifty dollars per seat flat.
Pharma, biotech, and device sales run under PhRMA Code or AdvaMed Code with therapeutic area targeting, formulary gates, and HCP engagement rules. The scoring criteria weight therapeutic area match, prescribing or ordering volume where ethically available, formulary posture, access and reimbursement, trial engagement, and compliance-aware cadence rather than title and company size alone.
No. The scoring model reads vendor-side account and contact records (HCPs, IDN leaders, formulary committee members, payer medical directors) and licensed prescribing or claims data where ethically available and permitted. Protected health information at the patient level is not a model signal and is not pulled into the scoring record. Strkr runs under a HIPAA posture with a Business Associate Agreement available.
The formulary signal reads tier status, prior authorization posture, and step-edit requirements on the IDN or payer record. The score reflects whether the account is open to the product, friction-constrained, or closed. The common failure of a scoring tool that treats all accounts as uniformly reachable gets avoided.
Yes. Target-type weighting, therapeutic area filters, volume tier bands, formulary weighting, and access-and-reimbursement weights are tunable on an admin page by the sales operations lead. The model recomputes nightly against the updated configuration. No Python notebook, no vendor engagement.
Strkr is HIPAA compliant with a Business Associate Agreement available. The SOC 2 Type II audit is in progress through 2026-Q4 with the controls catalog available on request. Claims and prescribing data pulls are logged against the compliance posture, role-based access controls scope visibility by territory and therapeutic area, and the audit log is available for every scoring change.
Yes. Account records, score history, driver citations, and model configuration are exportable through the open API in a structured format on demand. The data is not trapped behind the product UI. Vendor change becomes a workflow rather than a reconstruction project.
No sales call, no migration consultant, no four-month implementation. Enter your card, get 14 days of the full Pro tier, cancel any time before day 14 with zero charge. Spin up a workspace, import your CSV, and have something useful before lunch.
